Sign In
Buy VKTX
$32.37
+1.99 (+6.55%)
At Close: Jun 22, 2026
Viking Therapeutics: The Prime Target In The Obesity Gold Rush
10:05am, Thursday, 23'rd Oct 2025
Viking Therapeutics, Inc. is a clinical-stage biotech focused on metabolic and endocrine therapies, highlighted by its promising VK2735 obesity drug. VKTX's pipeline includes late-stage GLP-1/GIP agon
Viking Therapeutics, Inc. (VKTX) Q3 2025 Earnings Call Transcript
07:33pm, Wednesday, 22'nd Oct 2025
Viking Therapeutics, Inc. (NASDAQ:VKTX ) Q3 2025 Earnings Call October 22, 2025 4:30 PM EDT Company Participants Brian Lian - President, CEO & Director Gregory Zante - Chief Financial Officer Conferen
Viking Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
04:05pm, Wednesday, 22'nd Oct 2025
Conference call scheduled for 4:30 p.m. ET today Phase 3 VANQUISH Trials for Subcutaneous VK2735 in Obesity Proceeding on Schedule VK2735 Phase 1 Maintenance Dosing Study Underway Additional Phase 2a
Viking Therapeutics Announces Initiation of VK2735 Maintenance Dosing Clinical Trial in Patients with Obesity
07:05am, Tuesday, 21'st Oct 2025
Study to Explore Maintenance Dosing Regimens Following Initial Weight Loss with VK2735 Monthly Subcutaneous, Weekly Oral, and Daily Oral Regimens to be Evaluated SAN DIEGO , Oct. 21, 2025 /PRNewswire/
Truist Financial Corp Sells 525 Shares of Viking Therapeutics, Inc. $VKTX
03:49am, Sunday, 19'th Oct 2025
Truist Financial Corp cut its holdings in Viking Therapeutics, Inc. (NASDAQ: VKTX) by 6.3% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 7,832 sh
Viking Therapeutics, Inc. (VKTX) Stock Dips While Market Gains: Key Facts
06:45pm, Friday, 17'th Oct 2025
In the closing of the recent trading day, Viking Therapeutics, Inc. (VKTX) stood at $33.54, denoting a -3.44% move from the preceding trading day.
Pre-Q3 Earnings: Is Viking Therapeutics Stock a Portfolio Must-Have?
10:31am, Friday, 17'th Oct 2025
VKTX is likely to have headed into Q3 earnings with no product revenue, pipeline updates in focus and widening loss forecasts testing investor patience.
Eli Lilly vs. Viking Therapeutics Stock: Which Is the Best Growth Opportunity, According to Wall Street?
04:15am, Friday, 17'th Oct 2025
Eli Lilly (LLY -0.97%) and Viking Therapeutics (VKTX -1.02%) offer investors the chance to invest in one of today's highest-potential industries: weight loss drugs. The market for these products, wort
Viking Therapeutics to Report Financial Results for Third Quarter 2025 on October 22, 2025
04:05pm, Wednesday, 15'th Oct 2025
Conference Call Scheduled for Wednesday, October 22 at 4:30 p.m. Eastern Time SAN DIEGO , Oct. 15, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biophar
Viking Therapeutics, Inc. (VKTX) Registers a Bigger Fall Than the Market: Important Facts to Note
06:51pm, Tuesday, 14'th Oct 2025
Viking Therapeutics, Inc. (VKTX) closed at $33.05 in the latest trading session, marking a -2.54% move from the prior day.
Why Shares in Viking Therapeutics Surged This Week
01:37pm, Thursday, 09'th Oct 2025
Shares in Viking Therapeutics (VKTX 6.15%) were up more than 16% in the week to Thursday at 1 pm. The move comes after the announcement of another acquisition of a small-cap biopharmaceutical company
Viking Therapeutics: A Speculative Buy
09:44am, Saturday, 04'th Oct 2025
Viking Therapeutics offers a de-risked, asymmetric investment opportunity in the GLP-1 weight-loss drug market, trading below its risk-adjusted potential. VKTX's injectable and oral VK2735 both met Ph
Viking Therapeutics, Inc. (VKTX) Beats Stock Market Upswing: What Investors Need to Know
06:45pm, Thursday, 02'nd Oct 2025
In the closing of the recent trading day, Viking Therapeutics, Inc. (VKTX) stood at $27.88, denoting a +1.86% move from the preceding trading day.
Why This Beaten-Down GLP-1 Stock Could Be a Steal
09:15am, Tuesday, 30'th Sep 2025
Developing GLP-1 medicines is all the rage these days in the pharmaceutical and biotech industries. The market is growing rapidly, and many (if not most) leading drugmakers are looking to capitalize o
Viking Therapeutics: Overdue For Gains
02:00pm, Sunday, 28'th Sep 2025
Viking Therapeutics trades at yearly lows despite being ahead of recently acquired competitor Metsera in the weight-loss drug race. The Metsera deal suggests up to 150% upside to Viking, especially wh
